Biotech company Valo Health and AI healthcare firm nference have entered into a multi-year partnership to leverage AI and patient data in drug discovery and development.
The collaboration will integrate nference’s AI platform, which processes de-identified data from top academic medical centers, with Valo’s Opal Computational platform to enhance target discovery and precision medicine, according to a news release shared with Becker’s.
The partnership also grants Valo access to insights from physician notes, medical imaging, lab results and treatment data, which could help accelerate drug development.
